What molecular testing are you ordering in the adjuvant and neoadjuvant setting for GI cancers?

The answer depends on the specific GI cancer and the clinical setting (resectable vs. metastatic). Universal NGS is not recommended for resectable non-metastatic colon cancer. MMR/MSI testing and somatic PI3K pathway alterations (including PIK3CA) are recommended for stage II–III disease. Comprehens...

In colon cancer, I order MMR by ICH and MSI by NGS. I also order PIK3CA, etc., testing. In pancreatic cancer, I often get NGS testing given the high chance of recurrence.